fcn3 (Hycult Biotech)
Hycult Biotech is a verified supplier 
Hycult Biotech manufactures this product 
92
Structured Review
Hycult Biotech
fcn3
Fcn3, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/HK340/Ficolin-3%2C+Human%2C+ELISA+kit/pmc09874116-118-6-21
Average 92 stars, based on 11 article reviews
Fcn3, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 92/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/HK340/Ficolin-3%2C+Human%2C+ELISA+kit/pmc09874116-118-6-21
Average 92 stars, based on 11 article reviews
fcn3 - by Bioz Stars,
2026-09
92/100 stars
Images
1) Product Images from "Multiple-model machine learning identifies potential functional genes in dilated cardiomyopathy"
Article Title: Multiple-model machine learning identifies potential functional genes in dilated cardiomyopathy
Journal: Frontiers in Cardiovascular Medicine
doi: 10.3389/fcvm.2022.1044443
Figure Legend Snippet: The summed normalized weights of 20 differently expressed genes (DEGs) in six classifications machine learnings (MLs).
Techniques Used:
Figure Legend Snippet: The receiver operating characteristic (ROC) of SERPINA3, FRZB, and FCN3 between the control and dilated cardiomyopathy (DCM) groups. (A,C,E) The ROC of SERPINA3, FRZB, and FCN3 in the Training set; (B,D,F) the ROC of SERPINA3, FRZB, and FCN3 in the testing set.
Techniques Used: Control
Figure Legend Snippet: The immune correlation between diagnosis genes and immune cells. (A–C) The lollipop map and linear regression map in SERPINA3, FRAB, and FCN3.
Techniques Used:
Figure Legend Snippet: The plasma levels of SERPINA3, FRZB, and FCN3 in dilated cardiomyopathy (DCM) patients and healthy controls. ***Mean P < 0.001.
Techniques Used:
Related Articles
Activation Assay:Article Title: Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors. Article Snippet: MBL serum concentrations were measured in a double-antibody enzyme-linked immunosorbent assay (ELISA), with an in-house assay previously described by our group (32). .. Serum FCN-3 and MASP-2 concentrations and Enzyme-linked Immunosorbent Assay:Article Title: Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors. Article Snippet: MBL serum concentrations were measured in a double-antibody enzyme-linked immunosorbent assay (ELISA), with an in-house assay previously described by our group (32). .. Serum FCN-3 and MASP-2 concentrations and Article Title: Lectin pathway components and autoantibodies as novel immunological biomarkers in systemic lupus erythematosus (SLE) patients from Western India. Article Snippet: .. Assessment of serum levels of lectin pathway-associated PRMs and other serological parameters Serum concentrations of ficolin-1, ficolin-2, ficolin-3, and antigenic MBL levels were measured in 282 SLE patients using commercially available Article Title: Multiple-model machine learning identifies potential functional genes in dilated cardiomyopathy Article Snippet: .. All the plasma levels of SERPINA3, Article Title: Lectin pathway components and autoantibodies as novel immunological biomarkers in systemic lupus erythematosus (SLE) patients from Western India Article Snippet: .. Serum concentrations of ficolin-1, ficolin-2, ficolin-3, and antigenic MBL levels were measured in 282 SLE patients using commercially available other:Article Title: Ficolin-3 in chronic Chagas disease: Low serum levels associated with the risk of cardiac insufficiency. Article Snippet: Chagas disease (CD), a neglected tropical disease caused by infection with the protozoan parasite Trypanosoma cruzi, is a disease of rising public health concern.. It is endemic in Latin American countries, where the disease accounts for higher morbimortality than any other parasitic disease.1,2 CD is also emerging in nonendemic countries as a result of international travel and migration, including in highincome countries such as the United States, Australia, Japan and Spain.35 It is estimated that there are 68 million people affected by CD worldwide and another 65 million living at risk of developing the disease.6 For these reasons, CD poses a significant global burden, accounting for over USD $627 million in healthcare costs and 806 170 disabilityadjusted lifeyears (DALYs) annually.7 Acute T cruzi infection is frequently asymptomatic.. After a period of 48 weeks, the disease enters the chronic phase, characterized by Received: 4 June 2020 | Revised: 1 March 2021 | Accepted: 4 March 2021 DOI: 10.1111/pim.12829 Clinical Proteomics:Article Title: Multiple-model machine learning identifies potential functional genes in dilated cardiomyopathy Article Snippet: .. All the plasma levels of SERPINA3, |